The Correlation Of DNA Repair Capacity And Cisplatin Resistance In Advanced Non-Small-Cell Lung Cancer

OBJECTIVE To approach The Correlation of DNA repair capacity and cisplatin resistance in Advanced Non-Small-Cell Lung Cancer, and to provide theoretical supports for predicting the efficacy of cisplatin-based chemotherapy on Non-small-cell lung cancer patients.METHOD To measure the DNA repair capacity by the host cell reaction (HCR) assay by lymphocytes extracted from the peripheral blood of 96 cases of Non-small-cell lung cancer patients who was final diagnosed by pathology and could not take surgery. All of the patients accepted the cisplatin-based chemotherapy for at least 2 cycles. The differences of drug resistance to cisplatin-based chemotherapy and survival information after chemotherapy was observed and compared in groups with different DRC values. RESULT (1) The value of all 96 patients was 7.5% ±1.1%. The response rate(CR+PR) and failure risk(SD+PD) in DRC ≤6.7% group were 42.86% and 57.14% respectively. Compared with the 42.86% in DRC ≤ 6. 7% group, the response rate in 6. 7% < DRC < 8. 9% group was 39.39%. The X~2 value was 0.075, P value was 0.784, there was no difference between these two groups. Comparison between the failure risks in 6. 7%